Skip Navigation

Cardiovascular Research 2001 50(2):224-231; doi:10.1016/S0008-6363(00)00302-3
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Roden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roden, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Pharmacogenetics and drug-induced arrhythmias

Dan M. Roden*

Division of Clinical Pharmacology, Vanderbilt University School of Medicine, 532 Medical Research Building I, Nashville, TN 37232, USA

* Corresponding author. Tel.: +1-615-322-0067; fax: +1-615-343-4522 dan.roden{at}mcmail.vanderbilt.edu

Drugs are widely recognized to vary in the beneficial and undesirable effects they produce in human subjects. The understanding that variants (polymorphisms and mutations) in the human genome are common and may well modulate both disease and its response to drugs, is a critical new concept in understanding mechanisms of drug action and their variability in human subjects. Variability can arise because of variability in genes encoding molecules of drug disposition, in genes encoding molecules that drugs target, or in genes that modulate the overall activity of the complex biological systems within which drugs act. The evolving understanding of the genetic basis of variability in response to drugs used in the treatment of sudden cardiac death has important implications not only for the treatment of patients who have survived an episode, but also for helping formulate a framework for further understanding mechanisms of drug action at the genetic level.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
E. S. Kaufman
Disease-Causing Polymorphisms in the Spectrum of Long QT Syndrome Mutations.
J. Am. Coll. Cardiol., August 25, 2009; 54(9): 820 - 821.
[Full Text] [PDF]

Home page
 CirculationHome page
J. L. Anderson, B. D. Horne, S. M. Stevens, A. S. Grove, S. Barton, Z. P. Nicholas, S. F.S. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, et al.
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
Circulation, November 27, 2007; 116(22): 2563 - 2570.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
C. Antzelevitch
Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes
Europace, September 1, 2007; 9(suppl_4): iv4 - iv15.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. C. Lopshire and D. P. Zipes
Sudden Cardiac Death: Better Understanding of Risks, Mechanisms, and Treatment
Circulation, September 12, 2006; 114(11): 1134 - 1136.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
N. Ueda, D. P. Zipes, and J. Wu
Coronary occlusion and reperfusion promote early afterdepolarizations and ventricular tachycardia in a canine tissue model of type 3 long QT syndrome
Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H607 - H612.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Roberts
Genomics and Cardiac Arrhythmias
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 9 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R. Schimpf, C. Wolpert, F. Gaita, C. Giustetto, and M. Borggrefe
Short QT syndrome
Cardiovasc Res, August 15, 2005; 67(3): 357 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Kaab and E. Schulze-Bahr
Susceptibility genes and modifiers for cardiac arrhythmias
Cardiovasc Res, August 15, 2005; 67(3): 397 - 413.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. E. Arking, S. S. Chugh, A. Chakravarti, and P. M. Spooner
Genomics in Sudden Cardiac Death
Circ. Res., April 2, 2004; 94(6): 712 - 723.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T. M. Menendez, J. Brugada, G. D. Pollevick, C. Wolpert, et al.
Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG
Circulation, January 6, 2004; 109(1): 30 - 35.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Anantharam, S. M. Markowitz, and G. W. Abbott
Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 831 - 838.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. J. Ackerman, D. J. Tester, G. S. Jones, M. L. Will, C. R. Burrow, and M. E. Curran
Ethnic Differences in Cardiac Potassium Channel Variants: Implications for Genetic Susceptibility to Sudden Cardiac Death and Genetic Testing for Congenital Long QT Syndrome
Mayo Clin. Proc., December 1, 2003; 78(12): 1479 - 1487.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
C. R. Bezzina, A. O. Verkerk, A. Busjahn, A. Jeron, J. Erdmann, T. T. Koopmann, Z. A. Bhuiyan, R. Wilders, M. M.A.M. Mannens, H. L. Tan, et al.
A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization
Cardiovasc Res, July 1, 2003; 59(1): 27 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K.S. Siegl, I. Strang, A.T. Sullivan, R. Wallis, et al.
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development
Cardiovasc Res, April 1, 2003; 58(1): 32 - 45.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. J. Milan, T. A. Peterson, J. N. Ruskin, R. T. Peterson, and C. A. MacRae
Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish
Circulation, March 18, 2003; 107(10): 1355 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein
Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
A. F. James and J. C. Hancox
Sex, drugs and arrhythmia: are gender differences in risk of torsades de pointes simply a matter of testosterone?
Cardiovasc Res, January 1, 2003; 57(1): 1 - 4.
[Full Text] [PDF]

Home page
 CirculationHome page
N. Makita, M. Horie, T. Nakamura, T. Ai, K. Sasaki, H. Yokoi, M. Sakurai, I. Sakuma, H. Otani, H. Sawa, et al.
Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation
Circulation, September 3, 2002; 106(10): 1269 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
I. Splawski, K. W. Timothy, M. Tateyama, C. E. Clancy, A. Malhotra, A. H. Beggs, F. P. Cappuccio, G. A. Sagnella, R. S. Kass, and M. T. Keating
Variant of SCN5A Sodium Channel Implicated in Risk of Cardiac Arrhythmia
Science, August 23, 2002; 297(5585): 1333 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. M Spooner, S. G Priori, and R. J Myerburg
Spotlight on sudden cardiac death
Cardiovasc Res, May 1, 2001; 50(2): 173 - 176.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.